 LAVAL, QC and CAMBRIDGE, England, June 23, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, announced today that, Kedrion S.p.A Kedrion has exercised its option to acquire the remainder of the Companys plasma-derived business under the terms of the Share Purchase Agreement entered into by the Company and Kedrion. This acquisition would include the Ryplazim plasminogen, human-tvmh Ryplazim business operated through its subsidiaries, Prometic Bioproduction Inc., the Companys plasma-derived therapeutics manufacturing facility PBP, and Prometic Biotherapeutics Inc. PBT, holder of the biological license application BLA for Ryplazim and associated Rare Pediatric Disease Priority Review Voucher PRV. 